Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab combined with radiotherapy and chemotherapy after endoscopic surgery for sinonasal mucosal melanoma
ChiCTR2100045797Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Paranasal sinus melanoma, sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Overall survival. Started Apr 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Paranasal sinus melanoma
Beyond the preview
Go deeper on ChiCTR2100045797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045797.